ArticleAnnals of clinical and translational neurology2026

Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.

Mengcui Gui et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.